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HIGHLIGHTS
•

Smoking bans reduce second hand smoke (SHS) exposure and lead to improved health
outcomes.

•

The study quantified the association of SHS exposure on 10-year CVD risk in never
smokers in Greece.

•

SHS incurred a 2-fold elevated 10-year CVD risk, following adjustment for
confounding effects.

•

SHS induced 32% excess risk of 10-year CVD events in never smokers, with highest
rates in the workplace.

•

Effective implementation of national smoking bans is mandated to prevent SHS
attributable CVD.
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ABSTRACT
Background: Despite WHO Framework Convention of Tobacco Control (FCTC) adoption,
effective implementation of national smoking bans remains pending in several countries. This
study quantified the association of second hand smoke (SHS) exposure and 10-year
cardiovascular disease (CVD) among never smokers in such settings.
Methods: In 2001-2002, a sample of 1,514 males and 1,528 females (18-89 years old) were
randomly selected in Greece. Frequency and duration of SHS exposure (i.e. exposure extending
>30 minutes/day) within the home and/or workplace were assessed by interview. Following a
10-year follow-up period (2002-2012), incidence of non-fatal and fatal CVD (ICD-10) was
evaluated among n=2,020 participants. The analytic study sample consisted of all never
smokers (n=910).
Results: Despite national smoking ban implementation (2009), 44.6% (n=406) of never
smokers reported SHS exposure. While SHS exposed never smokers exhibited a more
favorable profile of CVD-related risk factors at baseline, they subsequently developed similar
10-year CVD incidence rates, at a younger mean age (p=0.001), to their non-exposed
counterparts. Following adjustment for several lifestyle and clinical factors, SHS exposed
never smokers exhibited a two-fold elevated 10-year CVD risk (adj. HR: 2.04, 95% CI: 1.432.92), particularly among women (adj. HR: 2.45, 95% CI: 1.45-4.06). SHS exposure accounted
for 32% excess Population Attributable Risk (PAR) for 10-year CVD events in never smokers,
with highest rates (PAR: 52%) being among those exposed in the workplace.
Conclusion: The prevention of SHS associated CVD and related healthcare costs mandates
additional strategies for securing the effective implementation of comprehensive WHO FCTC
based national smoking bans.
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INTRODUCTION
One third of adult never smokers are exposed to second hand smoke (SHS) [1], one of the most
frequent indoor air pollutants worldwide [2]. SHS exposure detrimentally impacts
cardiovascular health, attributing 2.8 million ischemic heart disease cases globally [2]. Recent
meta-analyses reveal that SHS exposure increases cardiovascular disease (CVD) risk by 23%
[3], including ischemic and coronary heart disease risk by 25-30% [4-6]. SHS impacts CVD
risk in a curvilinear dose-effect relationship, exhibiting detrimental effects even at low
exposure levels due to elevated side stream smoke toxicity and non-smoker’s low tolerance
levels to transient exposure [7]. The underlying pathophysiology entails the effects of nicotinic
stimulus on both the sympathetic system and vascular oxidative stress. Hence, the CVD effects
of SHS are similar to light active smoking [8, 9]. However, limited evidence exists regarding
its long-term effects upon fatal and non-fatal CVD [5, 10].
To diminish SHS exposure, national smoke-free bans are increasingly adopted. Such
bans protect non-smokers from adverse SHS effects and facilitate smokers to quit smoking,
while concomitantly deterring associated healthcare costs. The implementation of even partial
smoke-free bans is associated with beneficial health impacts regarding myocardial infarction
among passive smokers [11], whereas when fully implemented as national smoke-free bans a
17% reduction in hospital admission rates for acute coronary syndrome [5] and myocardial
infarction [12], as well as related healthcare costs [13] is observed. While WHO Framework
Convention on Tobacco Control (FCTC) policy measures have been realized during the past
decade in numerous countries, the effective implementation of smoking bans remains
suboptimal in several regions [14]. Specifically, in countries such as Greece, where smoking
prevalence rates in 2002 were 50% [15], despite the adoption of smoke-free legislation in 2009,
implementation remains feeble and persisting smoking rates at 40% remain one of the highest
in Europe [16]. Furthermore, SHS exposure among never smokers in Greece remains similar
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to those reported in 2002 [15], persisting at 40%, 51%, and 67% at work, home, and restaurants,
respectively [17]. Elucidating the long-term effects of SHS on CVD risk may facilitate
concerted public health actions for improving the effective implementation of smoke-free bans,
whilst concomitantly deterring CVD and its related healthcare costs [18, 19].
The present prospective cohort study aimed to quantify the association of SHS exposure
upon 10-year non-fatal and fatal CVD risk in a Greek population-based sample.

METHODS
Study design
The ATTICA Study [20] is a population-based, prospective cohort study implemented in
Attica, Greece, consisting of 78% urban and 22% rural municipalities. Random, multistage
sampling based on age and gender distributions of the reference population (defined by the
Hellenic National Statistical Service Census Survey of 2001) was applied. Sampling
procedures entailed enrolment of one participant per household. Persons with a history of
cardiovascular or atherosclerotic disease were excluded from sampling. Of 4,056 eligible
participants, 3,042 were enrolled (75% participation rate, including 1,514 men (mean age ±
standard deviation (SD) 46±13 y; range 18-87 y) and 1,528 women (aged 45±13 y; range: 18–
89 y)). The study sample did not differ from the general population with respect to age and
gender. All participants were interviewed by trained personnel (including cardiologists,
nutritionists, and nurse practitioners) who used a standardized questionnaire.
Baseline measurements
Socio-demographic characteristics
Baseline measurements were collected upon enrolment in 2001-2002. On-site interviews
included a questionnaire regarding demographic characteristics (e.g., age, gender, marital
status, financial status, and years of education completed, as proxy of socioeconomic status).
5

Years of education completed and mean annual income during years prior to baseline
examination were used to assess socioeconomic status (SES) defined as being low, moderate,
or high [20].
Smoking status and SHS exposure
Never smokers had never smoked, current smokers smoked ≥1 cigarette/day, and former
smokers had ceased smoking ≥1 year prior to enrolment. SHS exposure was evaluated based
on responses to the following: "Are you currently exposed to tobacco smoke from other people
for ≥30 minutes / day?". SHS exposure was evaluated separately for the workplace, home or
other venues, including public facilities and/or restaurants. Responses were categorized into
two levels: no SHS exposure or SHS exposure (≥30 minutes per day). To deter reporting bias,
participants’ responses were compared with relatives’ and/or accompanying persons’ reports,
rendering high concordance [21].
Lifestyle assessment
As previously detailed [20], dietary habits were assessed based on a validated semi-quantitative
food-frequency questionnaire [22], including average intake (per week or day) of several food
items during the past year. The Mediterranean diet score was used (range 0-55) to depict
adherence to the Mediterranean diet [23, 24].
The International Physical Activity Questionnaire (IPAQ) [25] was used as an index of
weekly energy expenditure using frequency (times/week), duration (in minutes/time) and
intensity of physical activity (in expended calories/time). Physical activity was leisure-time
activity of a certain intensity and duration, at least once/week during the past year, ranging
from <4 Kcal/min - >7 Kcal/min expended calories.
Anthropometric measurements and clinical assessment
Body mass index (BMI) was expressed as weight (kg) divided by standing height (m2), with
obesity being BMI >29.9 kg/m2. Waist (in cm) and hip (in cm) circumferences were measured
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using standard procedures. Subjects’ arterial blood pressure (BP) was measured in a sitting
position at the end of the physical examination, following ≥30 minutes at rest. BP was assessed
blindly by a trained cardiologist three times, from participants’ right arm which was relaxed
and well supported by a table, with an angle of 45o from the trunk (ELKA aneroid manometric
sphygmometer, Von Schlieben Co, West Germany). Systolic BP (SBP) was determined by the
first perception of sound (tapping quality), while diastolic BP (DBP) by phase V when
repetitive sounds become fully muffed. Hypertensive participants had mean systolic/diastolic
BP ≥140/90 mmHg or received antihypertensive medication [26].
Blood samples were collected from the antecubital vein between 8 to 10 AM, in a sitting
position after 12 hours of fasting and alcohol abstinence. Blood lipids (i.e., serum total
cholesterol, HDL-cholesterol and triglycerides) were measured with a Technicon automatic
analyzer RA-1000 and Technicon reagents, according to manufacturer instructions (Dade
Behring, Marburg, Germany); serum total cholesterol was measured using cholesterol esterase
and cholesterol oxidase in a colorimetric procedure. Hypercholesterolemia was defined as total
cholesterol levels ≥200 mg/dl or the use of lipids lowering agents (NCEP ATPIII [27]). LDL
cholesterol was calculated using the Friedewald formula: {total cholesterol} – {HDL
cholesterol} – 1/5 (triglycerides) (only in people who had triglycerides levels lower than 250
mg/dl). The intra and inter-assay coefficients of variation of cholesterol levels did not exceed
9%, triglycerides 4% and HDL 4%. Blood glucose levels (in mg/dl) were measured with a
Beckman Glucose Analyzer (Beckman Instruments, Fullerton, CA, USA). Diabetes mellitus
was defined as fasting blood sugar >125 mg/dl or administration of antidiabetic drugs. High
sensitivity C- reactive protein, fibrinogen, and homocysteine levels were measured by Behring
BNII automatic analyzer (Dade Behring, Marburg, Germany). High sensitivity IL-6 plasma

levels were measured by enzyme-linked immunosorbent assays (R&D systems Inc,
Minneapolis, Minnesota).
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Follow-up assessment
Follow-up assessments were conducted 10 years following baseline (median years to followup: 8.41 years; interquartile range (IQR): 5.0-10.0 years). Of the baseline population
(N=3,042), 10-year follow-up assessment was achieved in 2,583 participants (85%
participation rate; of those lost to follow-up, n=224 had missing/incorrect contact information
and n=235 declined). Among never smokers, 10-year follow-up assessment was achieved in
87% of participants (13% loss to follow-up rate, n=85 had missing/incorrect contact
information and n=75 declined). Complete CVD assessment was achieved in 2,020
participants, of which 910 were never smokers and constitute the analytic sample. Follow-up
examination included retrieval of detailed information from participants’ medical records.
Participants without accurate records were evaluated by interview, including assessment of
vital status (death from any cause or CVD) or development of coronary heart disease (including
myocardial infarction, angina pectoris, other identified forms of ischemia (WHO-ICD coding
410-414.9, 427.2, 427.6), heart failure of different types, and chronic arrhythmias (WHO-ICD
coding 400.0-404.9, 427.0 -427.5, 427.9) or stroke (WHO-ICD coding 430-438)).
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) and categorical variables
as absolute and relative frequencies (n, %). The normality of distributions of continuous
variables was assessed with P-P plots. The Student’s t-test, chi-squared test, and Likelihood
Ratio test were applied to compare normally distributed continuous, categorical, and ordinal
variables between groups, respectively [28]. To account for differing ages at baseline, the effect
of SHS exposure (as well as potential interactive effects of demographic, dietary, lifestyle, and
clinical characteristics) upon 10-year CVD incidence (outcome variable) was evaluated with
age-scaled Cox proportional hazard models and corresponding Hazard Ratios (HR, and 95%
Confidence Intervals, CI) in the overall study population and by gender. The proportionality
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assumption was assessed graphically. Adjusted population attributable risks (PARs) were
calculated based on 45% SHS prevalence rate [21]. Analyses were conducted with STATA
v.15 and based on two-sided tests (STATA Hellas, M.Psarros & Assoc., Greece).

RESULTS
Baseline exposure to SHS and 10-year CVD incidence in never smokers
Never smokers retained in the final analytic sample (n=910) did not differ from those lost to
follow-up with respect to gender (p=0.97), age (p=0.85), and/or SHS exposure (p=0.88). At
baseline, 44.6% (n=406) of never smokers were exposed to SHS. Among those exposed, 99.4%
(350/352) reported exposure in the workplace, while 37.0% (133/359) in their homes or other
venues, including public facilities and/or restaurants. Exposed never smokers were of younger
mean age and more often male. As compared to their non-exposed counterparts, at baseline
SHS exposed never smokers had a more favorable clinical profile regarding established CVDrelated risk factors, including lower mean levels of BMI, SBP, total serum cholesterol, LDL,
fibrinogen and IL-6 levels (all p’s<0.05). They did not differ from their non-exposed
counterparts with regard to the concomitant presence of hypertension and in fact less often had
hypercholesterolemia. Despite these favorable profiles, SHS exposed individuals subsequently
exhibited similar incidence rates of 10-year combined (n=137) (including fatal (n=23; 16.8%)
or non-fatal (n=114; 83.2%) CVD (SHS exposed vs non-exposed: 16.7% (n=68) vs 13.7%
(n=69); p=0.200), most notably at a younger age (namely approximately 7 years earlier) (mean
age ± SD: 58.4 ± 13.4 years vs 65.6 ± 11.6; p=0.001) (Table 2).
Baseline SHS exposed never smokers who subsequently developed 10-year CVD had
higher mean BMI and lower adherence to the Mediterranean Diet. They were approximately
five-fold (HR: 4.93; 95% CI: 2.78-8.77) more likely to have hypertension at baseline.
Furthermore, this group was in excess of six-fold (HR: 6.62; 95% CI: 3.09-14.21) and 70%
9

(HR: 1.70; 95% CI: 1.00-2.90) more likely to have diabetes and hypercholesterolemia. Finally,
exposed individuals with 10-year CVD had higher mean levels of fibrinogen and IL-6 at
baseline (all p’s <0.0001) as compared to their CVD-event free counterparts (Table 2).
SHS exposure and 10-year incidence of CVD
To account for differing ages at baseline, multivariate age-scaled Cox proportional hazard
models were applied to evaluate the effect of SHS exposure upon 10-year CVD in both the
overall study population and according to gender (Table 3). SHS was associated with a twofold elevated 10-year CVD risk (Adj. HR: 2.04, 95% CI: 1.43-2.92) even after adjusting for
various clinical (e.g., hypertension, hypercholesterolemia, and diabetes) and lifestyle (e.g.
adherence to the Mediterranean Diet and physical activity) variables, with females exhibiting
higher risk (Adj. HR: 2.45, 95% CI: 1.48-4.08) than males (Adj. HR: 1.97, 1.13-3.46).
Population Attributable Risk of SHS exposure on 10-year CVD incidence
Following adjustment for several clinical and lifestyle factors, SHS exposure accounted for
32% excess risk (i.e., Population Attributable Risk, PAR) of 10-year fatal and non-fatal CVD
events in never smokers (Table 4). Based on 45% SHS exposure prevalence rate in Greece, it
is estimated that 320 of 1000 CVD cases among never smokers could have been deterred had
SHS exposure been avoided. Corresponding 10-year CVD PAR rates among female and male
never smokers were 39% and 30%, respectively. Hence, 300 and 390 of 1000 male and female
CVD cases, respectively, could have been evaded had exposure been avoided. PAR rates were
highest among those exposed in the workplace; 590 male and 500 female of 1,000 cases could
have been deterred if exposure were avoided.

DISCUSSION
Smoking bans lead to SHS reduction and subsequent improved health outcomes [14], including
cardiovascular health [29], and attributable healthcare costs [30]. The study aimed to quantify
10

the association of SHS exposure upon 10-year non-fatal and fatal CVD risk among never
smokers in Greece, where the effective implementation of a national smoking ban remains
pending despite long-standing WHO FCTC based legislation. Despite the smoking ban, SHS
exposure rates among never smokers approximated 45%. While SHS exposed persons
exhibited a more favorable profile of CVD-related risk factors at baseline, they subsequently
developed 10-year CVD incidence rates comparable to their exposed counterparts, however at
a younger age. Following adjustment for confounding factors, SHS exposure incurred a twofold elevated 10-year CVD risk in never smokers, with highest rates observed in females. SHS
exposure accounted for 32% excess risk of 10-year CVD events in never smokers, with highest
rates (52%) regarding workplace exposure. Finally, at the population level, SHS exposure
accounts for 39% and 30% excess risk for 10-year CVD events among female and male never
smokers, respectively. These findings highlight the need for further public health actions
against SHS exposure in a country where several, albeit apparently unsuccessful, tobacco
control measures have been implemented recently.
Even limited levels of SHS exposure are associated with 25-30% increased CVD risk
[4-6]. Compared to non-exposed never smokers and following adjustment for potential
confounding factors, middle-aged never smokers with ≥25 h/week SHS exposure at home
displayed 7.86 fold elevated risk of peripheral arterial disease [31]. A recent meta-analyses
conducted among 23 prospective and 17 case-control studies revealed that the pooled relative
risk (RR) for CVD (n=38 studies) in never smokers exposed to SHS, as compared to their nonexposed counterparts, is 1.23 (95% CI: 1.16-1.31) [3]. The corresponding pooled risk rate
for all-cause mortality (n=12 studies) is 1.18 (95% CI: 1.10-1.27) [3], including a 5% increased
risk of death from coronary heart disease [32], which is notably augmented at 15% in women
[33]. SHS appears to induce vascular dysfunction by a multitude of mechanisms entailing
proinflammatory and prothrombotic cascades, including the enhanced aggregation of platelets,
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increased adherence of macrophages, acceleration of lipid peroxidation, and damage in
endothelial cells [2, 4, 34-36]. Interference of SHS with the production of nitric oxide permits
enhanced adhesion of inflammatory cells to the endothelium [29], further propagating
atherosclerotic processes. Ultimately, the combinatory effects of tissue remodeling,
prothrombotic processes, and augmented inflammatory response contribute to the
manifestation of arteriosclerotic vessels [36] and consequent onset of CVD.
The study findings reveal that, following adjustments for potential confounding effects,
SHS exposed never smokers remained approximately two-fold more likely to develop 10-year
fatal and non-fatal CVD. These findings are slightly higher than recent meta-analytic findings
showing that, never smokers aged ≥50 years have a 1.23 (95% CI: 1.16-1.31) increased risk of
CVD [3]. Disparities with our findings may be attributed to inherent differences regarding the
age distribution of populations investigated and SHS exposure being assessed solely within the
home. Even so, given the age-scaled statistical modelling procedures employed, our findings
add to the existing knowledge base a quantifiable association between SHS exposure and 10year CVD risk. Furthermore, previous work revealed that CVD risk factors include age, male
gender, and adherence to the Mediterranean diet [20], and were subsequently incorporated in
all models. As Hazard Ratios remained relatively stable as covariates were added to the models,
the observed association is unlikely due to unobserved confounding. To the best of our
knowledge, similar investigations have not been documented to date in smoke-free ban
settings.
SHS exposure accounted for 39% and 30% excess risk for 10-year CVD in female and
male never smokers, respectively. A significant interaction between gender and ETS in relation
to 10-year CVD was not documented (HR:0.97; 95% CI:0.97-2.31). In regions such as France
characterized by high smoking prevalence rates, SHS exposure rates has decreased over time
in both men and women [37]. However, women report higher rates of SHS exposure at home
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[38]. Also, exposed women have a 15% augmented attributable mortality rate due to heart
disease [33]. Our findings corroborate that a gender disparities exist between SHS exposure
and subsequent CVD risk. Additionally, our findings reveal that 320 and 520 of 1000 10-year
CVD incident cases could have been avoided if SHS exposure been deterred overall and in the
workplace, respectively. These findings are in agreement with previous reports [39, 40]. In an
attempt to explore the paths by which SHS may affect CVD risk, we revealed that when
introducing various demographic, lifestyle, clinical and/or biochemical factors, the effect size
measure of SHS on 10-year CVD risk was mediated, but still remained significantly associated,
with an approximately two-fold elevated risk of 10-year CVD. Hence, it is speculated that in
never smokers SHS exposure is an independent risk factor for 10-year CVD risk, propagating
the disease at a younger age.
Country-wide smoking bans are decisive in improving cardiovascular health and
reducing attributable healthcare costs [30], particularly in settings such as Greece which has
one of the highest tobacco consumption rates in Europe [21] and is concomitantly challenged
by financial austerity measures. However, effective implementation of bans often remains
poor, likely due to enforcement-related difficulties [14]. The most recent WHO Global
Tobacco Adult Survey underlines the necessity for overturning feeble implementation rates of
smoke free bans in countries such as Greece [21], where despite rising tobacco cessation rates,
SHS remains elevated. Specifically, the Greek Parliament adopted the WHO FCTC in 2005, a
smoke-free law in 2010 (Law 3868/2010), and national smoking ban in 2011 [21].
Nevertheless, SHS exposure at the population level remains at 90%, with rates among never
smokers being 40.0%, 51.1%, and 67.1% in workplaces, homes, and restaurants. Based on
persistently high SHS exposure rates alone, it is evident that implementation of the existing
smoke-free ban in public and/or workplaces remains inadequate [17]. Hence, more effective
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implementation, monitoring and evaluation of smoke-free bans are needed to diminish SHS
exposure and attributable CVD risk.
For the potential of the WHO FCTC to be achieved in such settings, challenges
(including ineffective implementation of guidelines and insufficient capacity and/or financial
support) need to be addressed and progress must be escalated in related policy domains [14],
preferably through horizontal policy actions and engagement of multidisciplinary stakeholders.
To this effect, the study findings may enhance the evidence base necessary for developing
horizontal policy actions, including i.e. concerted actions regarding FCTC Article 8 (e.g.
protection from SHS exposure), Article 20 (e.g. research that addresses the consequences of
SHS), and Article 22 (e.g., facilitation of the transfer of knowledge related to tobacco control).
Given that particularly children are often additionally exposed to third-hand smoke pollutants
and toxicants [41], further actions are mandated. Specifically, since evidence arising from
preliminary animal studies regarding the CVD-related health impacts of third-hand smoke are
limited albeit alarming [42, 43], future epidemiologic investigations may facilitate risk
assessment and inform current smoking bans by evaluating both the differential and cumulative
risks of second- and third- hand smoke exposure upon CVD outcomes.
Strengths and Limitations
The study strengths include the prospective cohort study design applied in a representative
randomly selected population-based sample from the most densely populated urban district of
Greece. Length of follow-up assessment extended 10 years, allowing for sufficient time to
evaluate CVD outcomes whilst avoiding bias due to disease latency. The study limitations
include that SHS exposure was based on self-report prone to a misclassification bias. Due to
the study design employed, external validation of SHS exposure by external validation methods
such as cotinine levels or confirmation by bystanders was not feasible. However, the observed
SHS exposure rates agree with other similar reports [17], albeit both unconfirmed via
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biomarkers, such as cotinine levels. In addition, while adherence to the Mediterranean Diet
(MedDietScore) was measured, complete dietary analysis for nutrient components was not
assessed. However, due to the extended follow-up period, dietary patterns likely more
accurately predict CVD risk as they provide insights regarding how comprehensive nutritional
intake affects disease risk. Finally, potential treatment effects for other underlying diseases
(e.g., hypertension, hypercholesterolemia, and diabetes mellitus) upon CVD risk were not
assessed. Even so, treatment effects would likely bias findings towards the null hypothesis and
hence the effects observed are likely an underestimation of true effects.
Conclusions
The prevention of SHS associated CVD, as well as respective healthcare costs, mandates the
adoption of additional concerted strategies for achieving effective national smoking bans and
comprehensive tobacco control programs, especially among populations with persistent high
rates of smoking habits.
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Table 1. Baseline characteristics of the ATTICA study participants who were never smokers,

according to the frequency of exposure to second hand smoke (SHS) (n=910)
Overall

Without SHS

With SHS

exposure

exposure

(n=910)

(n=504)

(n=406)

Age of participants (years)

46.2 ± 15.4

48.6 ± 15.7

43.1 ± 14.5

<0.0001

Male gender, %

344 (37.8)

176 (34.9)

168 (41.4)

0.046

Socioeconomic status

p

0.316
Low, %

91 (17.3)

32 (20.8)

59 (15.9)

Medium, %

247 (47.0)

66 (42.9)

181 (48.8)

High, %

187 (35.6)

56 (36.4)

131 (35.3)

Body Mass Index (Kg/m2)

26.2 ± 4.5

26.4 ± 4.6

25.8 ± 4.4

0.046

Obesity, %

160 (17.9)

94 (19.0)

66 (16.5)

0.334

Physical inactivity

501 (55.1)

270 (53.6)

231 (56.9)

0.316

MedDietScore (range 0 to 55)

26.0 ± 7.0

25.7 ± 6.8

26.4 ± 7.1

0.113

Ethanol intake (g/day)

10.2 ± 12.7

13.0 ± 13.6

8.1 ± 11.6

<0.0001

Systolic Blood Pressure (mm Hg)

123.9 ± 19.3

126.0 ± 19.0

121.2 ± 19.2

<0.0001

Diastolic Blood Pressure (mm Hg)

79.1 ± 12.0

79.4 ± 11.8

78.7 ± 12.3

0.443

Hypertension, %

281 (33.2)

162 (34.3)

119 (31.7)

0.427

193.6 ± 40.8

198.0 ± 41.1

188.0 ± 39.9

<0.0001

Hypercholesterolemia, %

367 (40.3)

230 (45.6)

137 (33.7)

<0.0001

Fasting blood glucose (mg/dL)

92.4 ± 21.2

92.2 ±18.8

92.6 ± 23.8

0.793

71 (7.8)

40 (7.9)

31 (7.6)

0.866

Total serum cholesterol (mg/dL)

Diabetes Mellitus, %

20

High Density Lipoprotein (mg/dL)

51.3 ± 13.2

50.8 ± 12.5

52.0 ± 13.9

0.177

Low Density Lipoprotein (mg/dL)

121.7 ± 36.3

125.3 ± 35.4

116.7 ± 36.9

0.002

Fibrinogen (mg/dL)

313.9 ± 73.2

319.7 ± 73.0

306.0 ± 72.9

0.012

11.7 ± 5.7

12.0 ± 5.0

11.4 ± 6.2

0.216

C-reactive protein (mg/dL)*

0.9 (1.8)

1.0 (1.8)

0.9 (1.7)

0.749

IL-6 (pg/ml)*

1.4 (0.4)

1.4 (0.4)

1.3 (0.4)

0.016

Homocysteine (μmol/L)

Continuous variables are presented as mean±standard deviation (M±SD), and categorical variables
as absolute and relative frequencies (n(%)).P-values referring to differences between CVD-events
and CVD-free events during the 10-year follow-up, derived using either the Student’s t-test or the
Pearson chi-square test for the continuous and the categorical characteristics, respectively.
Differences between groups regarding ordinal variables were compared with the Likelihood Ratio
test. *Expressed as median (interquartile range, IQR).
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Table 2. Baseline characteristics of the ATTICA study’s participants who were never smokers in relation to the 10-year fatal or non-fatal incidence of
CVD, according to exposure to second hand smoke (SHS) (n=910)
Status at 10-year follow–up among those
Status at 10-year follow–up among those
without SHS exposure (n=504)
CVD event free

CVD events

(n=435)

(n=69)

Age of participants (years)

45.9 ± 14.5

65.6 ± 11.6

Male gender, %

151 (34.7)

25 (36.2)

Socioeconomic status

with SHS exposure (n=406)
p

CVD event free

CVD events

(n=338)

(n=68)

<0.0001

40.1 ± 12.6

58.4 ± 13.4

0.806

135 (39.9)

33 (48.5)

<0.0001

p

<0.0001
0.189
<0.0001

Low, %

26 (17.8)

6 (75.0)

37 (11.7)

22 (40.7)

Medium, %

64 (43.8)

2 (25.0)

160 (50.5)

21 (38.9)

High, %

56 (38.4)

0 (0.0)

120 (37.9)

11 (20.4)

Body Mass Index (Kg/m2)

26.2 ± 4.5

28.0 ± 5.0

0.002

25.5 ± 4.4

27.6 ± 4.2

<0.0001

Obesity, %

75 (17.6)

19 (27.9)

0.043

50 (15.0)

16 (24.2)

0.064

Physical inactivity

234 (53.8)

36 (52.2)

0.802

195 (57.7)

36 (52.9)

0.470

MedDietScore (range 0 to 55)

26.2 ± 6.5

22.1 ± 7.8

<0.0001

27.1 ± 6.9

22.8 ± 7.2

<0.0001

Ethanol intake (g/day)

12.1 ± 13.3

21.8 ± 13.5

0.010

7.7 ± 11.8

10.9 ± 10.2

0.187

Systolic Blood Pressure (mm Hg)

124.4 ± 18.2

136.1 ± 22.0

<0.0001

118.3 ± 17.0

136.6 ± 22.7

<0.0001
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Diastolic Blood Pressure (mm Hg)

79.2 ± 11.7

80.2 ± 12.3

Hypertension, %

128 (31.3)

34 (54.0)

197.6 ± 42.4

200.6 ± 31.5

193 (44.4)

37 (53.6)

90.7 ± 15.7

77.6 ± 11.8

85.0 ± 13.3

<0.0001

80 (25.6)

39 (62.9)

<0.0001

0.577

184.2 ± 37.6

208.2 ± 45.4

<0.0001

0.152

107 (31.7)

30 (44.1)

102.1 ± 30.8

<0.0001

90.4 ± 21.6

104.0 ± 30.6

<0.0001

21 (4.8)

19 (27.5)

<0.0001

15 (4.4)

16 (23.5)

<0.0001

HDL-cholesterol (mg/dL)

51.3 ± 12.7

47.4 ± 10.9

0.026

52.6 ± 14.1

48.8 ± 12.4

LDL-cholesterol (mg/dL)

125.2 ± 36.0

125.8 ± 32.1

0.902

113.6 ± 35.2

135.2 ± 41.5

<0.0001

Fibrinogen (mg/dL)

315.2 ± 69.2

347.5 ± 89.2

0.002

298.8 ± 69.1

349.2 ± 80.5

<0.0001

Homocysteine (μmol/L)

11.8 ± 4.6

12.9 ± 7.1

0.229

11.2 ± 6.5

12.3 ± 4.0

0.289

C-reactive protein (mg/L)*

0.9 (1.7)

1.4 (1.8)

0.134

0.9 (1.5)

1.3 (2.3)

0.104

IL-6 (pg/ml) *

1.3 (0.4)

1.7 (0.3)

<0.0001

1.3 (0.4)

1.6 (0.6)

<0.0001

Total serum cholesterol (mg/dL)
Hypercholesterolemia, %
Fasting blood glucose (mg/dL)
Diabetes Mellitus, %

0.530
<0.0001

0.047

0.054

Continuous variables are presented as mean±standard deviation (M±SD), and categorical variables as absolute and relative frequencies (n(%)).P-values
referring to differences between CVD-events and CVD-free events during the 10-year follow-up, derived using either the Student’s t-test or the Pearson
chi-square test for the continuous and the categorical characteristics, respectively. Differences between groups regarding ordinal variables were
compared with the Likelihood Ratio test. *Expressed as median (interquartile range, IQR).

23

Table 3. Multivariate age-scaled Cox Proportional Hazards models that evaluated the association
between SHS on 10-year CVD risk among ATTICA Study never smokers, taking into account the
effect of various clinical and lifestyle factors. Results are presented as Adjusted Hazard Ratios
(Adj. HR) and 95% Confidence Intervals (CI).
Model 1
Model 2
Model 3
Adj. HR (95% CI)

Adj. HR (95% CI)

Adj. HR (95% CI)

2.14 (1.52-3.00)

2.03 (1.42-2.90)

2.04 (1.43, 2.92)

Hypertension (Y/N)

1.23 (0.86-1.78)

1.18 (0.81-1.73)

Hypercholesterolemia (Y/N)

1.18 (0.82-1.69)

1.19 (0.82-1.71)

Diabetes (Y/N)

1.08 (0.71-1.63)

1.08 (0.71-1.65)

All never smokers
SHS exposure (Y/N)

MedDietScore (per 1/55)

1.01 (0.98-1.04)

Physically active (Y/N)

1.26 (0.88-1.80)

Male never smokers
SHS exposure (Y/N)

2.02 (1.20-3.40)

2.05 (1.17-3.57)

1.97 (1.13-3.46)

Hypertension (Y/N)

1.43 (0.78-2.61)

1.39 (0.75-2.56)

Hypercholesterolemia (Y/N)

1.32 (0.74-2.33)

1.39 (0.77-2.49)

Diabetes (Y/N)

0.68 (0.36-1.29)

0.66 (0.34-1.27)

MedDietScore (per 1/55)

1.02 (0.98-1.06)

Physically active (Y/N)

1.16 (0.66-2.06)

Female never smokers
SHS exposure (Y/N)

2.22 (1.40-3.51)

2.30 (1.40-3.77)

2.45 (1.48-4.08)

Hypertension (Y/N)

1.33 (0.81-2.16)

1.28 (0.77-2.11)

Hypercholesterolemia (Y/N)

1.02 (0.63-1.67)

1.04 (0.62-1.73)

Diabetes (Y/N)

1.57 (0.87-2.83)

1.66 (0.90-3.06)

MedDietScore (per 1/55)

1.01 (0.97-1.05)

Physically active (Y/N)

1.49 (0.91-2.44)
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Table 4. Age- scaled adjusted Cox proportional hazard ratios and corresponding population
attributable risks (PAR) for 10-year fatal or non-fatal incidence of CVD (outcome) among
never smoker participants in the ATTICA study, according to gender
Adjusted Hazard Ratio
Adjusted Population
(95% Confidence Interval)

Attributable Risk (%)

Overall SHS exposure

2.04 (1.43-2.92)

32

SHS exposure at home,

1.47 (0.85-2.54)

17

3.43 (1.53-7.72)

52

Overall SHS exposure

1.97 (1.13-3.46)

30

SHS exposure at home,

2.19 (0.83-5.78)

35

4.21 (1.20-14.77)

59

Overall SHS exposure

2.45 (1.48-4.08)

39

SHS exposure at home,

1.40 (0.67-2.95)

15

3.24 (1.04-10.07)

50

All never smokers

restaurants, and other venues
SHS exposure at the workplace
Male never smokers

restaurants, and other venues
SHS exposure at the workplace
Female never smokers

restaurants, and other venues
SHS exposure at the workplace

Adjusted Hazard Ratios (Adj. HR) according to age, clinical (including hypertension,
hypercholesterolemia), and type 2 diabetes mellitus) and lifestyle (including MedDiet Score and
physical activity levels) characteristics.
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